Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...

As the new year sparks a wave of weight loss resolutions and millions turn to weight loss medications, rising costs and the growing popularity of compounded alternatives have raised critical questions ...

Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

In the pursuit of optimal health and wellness, hydration often takes center stage. Many individuals, particularly seniors, ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, Mounjaro and Zepbound, remains massive, their sales were hurt due to ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

Medicare drug plans can now cover Eli Lilly & Co.'s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that's expected to prove a big boost for the drug company.